A retrospective, peer-reviewed study by the Henry Ford Health System in Detroit found that hospitalized Covid-19 patients who received the anti-malaria drug hydroxychloroquine early in their stay were half as likely to die as the control group, the nonprofit hospital announced Thursday. The study’s author, Dr. Marcus Zervos, attributed the results to the timing of patients receiving HCQ.

The Ford press release stated:

“In a large-scale retrospective analysis of 2,541 patients hospitalized between March 10 and May 2, 2020, across the system’s six hospitals, the study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients had documented serious heart abnormalities; however, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a treatment for COVID-19.”